Methylation Tumor Marker EP8 for Accurate Multi-Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tumor markers based on DNA methylation have limitations in sensitivity, specificity, and lack a unified standard for clinical application, leading to misdiagnosis and inadequate detection of tumor sources and metastasis due to the heterogeneity of tumors and complexity of DNA sources in blood samples.
Innovation Solution
A methylation-based tumor marker, STAMP, targeting specific hypermethylated sites in tumor DNA, including polynucleotides with modified CpG sites, is used to develop detection agents and kits for identifying abnormal hypermethylation patterns in various tumor types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional tumor marker detection methods (CTA, EIA, ELISA) are used, then the detection process is simple, but the detection precision and sensitivity are insufficient for early cancer diagnosis
Solution Approach 1:
The detection system is segmented into multiple functional modules: capture antibody-coated magnetic beads for specific antigen binding, fluorescently labeled detection antibodies for signal generation, and flow cytometry equipment for high-throughput analysis. This segmentation allows each component to be optimized independently while achieving overall high precision detection.
Solution Approach 2:
Magnetic beads coated with capture antibodies serve as intermediaries that concentrate tumor markers from complex biological samples. The fluorescently labeled detection antibodies act as intermediaries that convert the binding event into a detectable fluorescent signal, enabling high-sensitivity detection.
2Measurement precision
If traditional tumor marker detection methods are used, then the operation is straightforward, but the detection sensitivity cannot meet early cancer diagnosis requirements
Solution Approach 1:
The assay system performs self-concentration through the magnetic bead-antigen binding, eliminating the need for complex sample pre-concentration steps. The fluorescent labeling provides self-amplification of the detection signal, reducing the need for sophisticated signal amplification procedures.
Solution Approach 2:
The detection platform uses universal magnetic bead carriers and fluorescently labeled antibodies that can be applied to detect various tumor markers (CEA, CA19-9, CA125, etc.) through the same basic protocol, maintaining ease of operation across different marker detections while achieving high sensitivity.
3Measurement precision
If methylation-based modified tumor marker detection is implemented, then the detection precision and sensitivity are significantly improved, but the detection cost and technical requirements increase
Solution Approach 1:
The invention changes the detection parameter from measuring total tumor marker concentration to measuring methylation-specific tumor marker sequences. This parameter change enables differentiation between malignant and benign conditions, significantly improving diagnostic accuracy despite the increased technical complexity.
Solution Approach 2:
The assay performs preliminary enrichment of methylation-specific DNA sequences using methylation-specific capture probes before detection. This preliminary action concentrates the target analyte and removes interfering substances, improving detection accuracy while reducing the need for expensive repeated testing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
STAMP provides high accuracy in tumor detection and diagnosis, enabling effective clinical diagnosis, auxiliary diagnosis, and prognosis monitoring across multiple tumor types.
Implementation Method 1
coating magnetic beads with capture antibodies
Implementation Method 2
fluorescently labeled detection antibodies were added to the reaction solution, and the mixture was detected by flow cytometry
Data Source
Figure 1~3
Figure 4~6
Figure 7~12
AI summary
Provided are an isolated polynucleotide and a use thereof, wherein the isolated polynucleotide is the polynucleotide shown in SEQ ID NO:1 or a fragment or complementary nucleic acid thereof at a modified CpG site. Further provided are the use of the polynucleotide for preparing a tumor detection reagent or a kit, a preparation method, a reagent and a use thereof, a kit, and a method for the in-vitro detection of the methylation profile of a sample.